Loading...

Synlogic

DB:MINA
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
MINA
DB
$202M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Synlogic has significant price volatility in the past 3 months.
MINA Share Price and Events
7 Day Returns
-0.3%
DB:MINA
0.3%
DE Biotechs
2.3%
DE Market
1 Year Returns
-24.3%
DB:MINA
-7.9%
DE Biotechs
-7.2%
DE Market
MINA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Synlogic (MINA) -0.3% 6.4% 17.9% -24.3% - -
DE Biotechs 0.3% 3.1% -6.5% -7.9% 43.5% 7.6%
DE Market 2.3% 3.1% 8.8% -7.2% 9.3% 12.3%
1 Year Return vs Industry and Market
  • MINA underperformed the Biotechs industry which returned -7.9% over the past year.
  • MINA underperformed the Market in Germany which returned -7.2% over the past year.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Synlogic undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Synlogic. This is due to cash flow or dividend data being unavailable. The share price is €7.181.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Synlogic's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Synlogic's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:MINA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-2.03
NasdaqGM:SYBX Share Price ** NasdaqGM (2019-04-17) in USD $7.96
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 23.37x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.43x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Synlogic.

DB:MINA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:SYBX Share Price ÷ EPS (both in USD)

= 7.96 ÷ -2.03

-3.92x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synlogic is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Synlogic is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Synlogic's expected growth come at a high price?
Raw Data
DB:MINA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.92x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts
-1.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.31x
Germany Market PEG Ratio Median Figure of 272 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Synlogic, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Synlogic's assets?
Raw Data
DB:MINA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.89
NasdaqGM:SYBX Share Price * NasdaqGM (2019-04-17) in USD $7.96
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.89x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:MINA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:SYBX Share Price ÷ Book Value per Share (both in USD)

= 7.96 ÷ 4.89

1.63x

* Primary Listing of Synlogic.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Synlogic is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Synlogic's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Synlogic has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Synlogic expected to perform in the next 1 to 3 years based on estimates from 6 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-1.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Synlogic expected to grow at an attractive rate?
  • Unable to compare Synlogic's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Synlogic's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Synlogic's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:MINA Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:MINA Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 6 Analysts -1.6%
DB:MINA Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 6 Analysts 68.6%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.6%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:MINA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:MINA Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 141 -59 -12 4
2022-12-31 18 -98 -98 4
2021-12-31 0 -74 -92 4
2020-12-31 2 -56 -73 5
2019-12-31 2 -51 -58 6
DB:MINA Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 3 -42 -48
2018-09-30 3 -43 -48
2018-06-30 1 -40 -49
2018-03-31 3 -37 -44
2017-12-31 2 -31 -40
2017-09-30 2 -29 -36
2017-06-30 2 -26 -29
2017-03-31 0 -23 -24
2016-12-31 0 -20 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Synlogic is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Synlogic's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:MINA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below

All data from Synlogic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MINA Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 0.34 1.36 -1.25 4.00
2022-12-31 -2.06 -1.11 -2.54 4.00
2021-12-31 -2.38 -1.64 -2.97 4.00
2020-12-31 -2.35 -1.81 -2.93 7.00
2019-12-31 -2.17 -1.83 -2.65 7.00
DB:MINA Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -2.03
2018-09-30 -2.24
2018-06-30 -2.89
2018-03-31 -3.89
2017-12-31 -6.00
2017-09-30 -11.27
2017-06-30 -26.51
2017-03-31 -18.86
2016-12-31 -13.30

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Synlogic will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Synlogic's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Synlogic has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Synlogic performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Synlogic's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Synlogic does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Synlogic's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Synlogic's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Synlogic's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Synlogic Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:MINA Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 2.52 -48.44 14.92 38.03
2018-09-30 2.52 -48.20 15.36 36.90
2018-06-30 0.83 -49.38 15.89 35.92
2018-03-31 2.69 -44.17 14.19 33.58
2017-12-31 2.44 -40.38 12.93 30.34
2017-09-30 2.44 -35.53 10.48 27.73
2017-06-30 2.44 -28.91 8.53 22.91
2017-03-31 0.44 -24.49 7.15 17.80
2016-12-31 0.44 -20.95 6.40 15.01
2015-12-31 -8.53 4.50 4.02

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Synlogic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Synlogic has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Synlogic improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Synlogic's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Synlogic has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Synlogic's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Synlogic's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Synlogic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Synlogic's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Synlogic's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 261.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Synlogic Company Filings, last reported 3 months ago.

DB:MINA Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 124.10 0.48 122.73
2018-09-30 135.03 0.57 132.62
2018-06-30 144.62 0.69 143.21
2018-03-31 128.77 0.78 125.80
2017-12-31 85.04 0.89 87.03
2017-09-30 95.57 0.43 96.57
2017-06-30 66.38 0.27 66.83
2017-03-31 32.91 0.32 34.15
2016-12-31 13.50 0.38 14.59
2015-12-31 3.36 0.09 6.18
  • Synlogic's level of debt (0.4%) compared to net worth is satisfactory (less than 40%).
  • Unable to establish if Synlogic's debt level has increased without past 5-year debt data.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Synlogic has sufficient cash runway for 2.6 years based on current free cash flow.
  • Synlogic has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 45.7% each year.
X
Financial health checks
We assess Synlogic's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Synlogic has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Synlogic's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Synlogic dividends. Estimated to be 0% next year.
If you bought €2,000 of Synlogic shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Synlogic's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Synlogic's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:MINA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 6 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3.1%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:MINA Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Synlogic has not reported any payouts.
  • Unable to verify if Synlogic's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Synlogic's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Synlogic has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Synlogic's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Synlogic's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Synlogic afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Synlogic has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Synlogic's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Aoife Brennan
AGE 42
TENURE AS CEO 0.9 years
CEO Bio

Dr. Aoife M. Brennan, M.D. M.B., B.Ch. has been a Director at Ra Pharmaceuticals, Inc since September 21, 2018. Dr. Brennan serves Chief Medical Officer of Synlogic, Inc. since September 12, 2016 and had served as its Interim President & CEO from May 2018 to October 2, 2018. She has been the President, Chief Executive Officer & Director of Synlogic Inc. since October 2, 2018. Dr. Brennan is responsible for the oversight and direction of the Synlogic's clinical development strategy and operations. Dr. Brennan joined Synlogic following six years at Biogen, where she was in roles of increasing responsibility and served as vice president and head of the Rare Disease Innovation Unit, which included programs ranging from pre-clinical to commercial. She has also led programs across multiple therapeutic areas including the late phase development of nusinersen for spinal muscular atrophy and ALPROLIX and ELOCTATE, treatments for Hemophilia B and Hemophilia A. She served as Senior Medical Director of Clinical Development at Biogen Inc. (alternate name, Biogen Idec Inc.). Prior to joining Biogen, Dr. Brennan was Director of Clinical Development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program. Dr. Brennan holds a medical degree from Trinity College Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. Prior to joining the biotechnology industry, she was a Clinical Research Fellow in the Division of Endocrinology, Diabetes, and Metabolism at Beth Israel Deaconess Medical Center and the Joslin Diabetes Center in Boston,

CEO Compensation
  • Aoife's compensation has increased whilst company is loss making.
  • Insufficient data for Aoife to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Synlogic management team in years:

0.9
Average Tenure
54
Average Age
  • The average tenure for the Synlogic management team is less than 2 years, this suggests a new team.
Management Team

Peter Barrett

TITLE
Executive Chairman
COMPENSATION
$154K
AGE
65
TENURE
0.9 yrs

JC Gutierrez-Ramos

TITLE
COMPENSATION
$2M
AGE
55

Aoife Brennan

TITLE
President
AGE
42
TENURE
0.9 yrs

Tim Lu

TITLE
Co-Founder

Jim Collins

TITLE
Co-Founder

Todd Shegog

TITLE
Chief Financial Officer
AGE
53
TENURE
2.6 yrs

Tony Awad

TITLE
Head of Technical Operations
TENURE
0.3 yrs

Paul Miller

TITLE
Chief Scientific Officer
COMPENSATION
$437K
AGE
58
TENURE
4.6 yrs

Liz Wolffe

TITLE
Head of Investor Relations & Corporate Communications

Maiken Keson-Brookes

TITLE
General Counsel
AGE
45
Board of Directors Tenure

Average tenure and age of the Synlogic board of directors in years:

3.1
Average Tenure
58
Average Age
  • The tenure for the Synlogic board of directors is about average.
Board of Directors

Peter Barrett

TITLE
Executive Chairman
COMPENSATION
$154K
AGE
65
TENURE
2.1 yrs

Aoife Brennan

TITLE
President
AGE
42

Ed Mathers

TITLE
Director
COMPENSATION
$174K
AGE
58
TENURE
6.5 yrs

Mike Powell

TITLE
Director
COMPENSATION
$190K
AGE
63
TENURE
6.5 yrs

Rick Shea

TITLE
Director
COMPENSATION
$146K
AGE
66
TENURE
1.7 yrs

Chau Khuong

TITLE
Director
COMPENSATION
$144K
AGE
42
TENURE
3.2 yrs

Charlotte Hubbert

TITLE
Observer

Nick Leschly

TITLE
Independent Director
COMPENSATION
$315K
AGE
45
TENURE
3.1 yrs

Patricia Hurter

TITLE
Independent Director
TENURE
0.2 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Synlogic's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Synlogic has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered synthetic biotic medicine to treat immuno-oncology solid tumors. It has collaboration agreements with AbbVie S.à.r.l. to develop synthetic biotic medicines for the treatment of inflammatory bowel diseases; and Ginkgo Bioworks to enable the discovery of new living medicines. Synlogic, Inc. is headquartered in Cambridge, Massachusetts.

Details
Name: Synlogic, Inc.
MINA
Exchange: DB
Founded:
$178,916,108
25,400,495
Website: http://www.synlogictx.com
Address: Synlogic, Inc.
301 Binney Street,
Suite 402,
Cambridge,
Massachusetts, 02142,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM SYBX Common Shares Nasdaq Global Market US USD 28. Aug 2017
DB MINA Common Shares Deutsche Boerse AG DE EUR 28. Aug 2017
MUN MINA Common Shares Boerse Muenchen DE EUR 28. Aug 2017
Number of employees
Current staff
Staff numbers
74
Synlogic employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 00:01
End of day share price update: 2019/04/17 00:00
Last estimates confirmation: 2019/03/13
Last earnings filing: 2019/03/12
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.